SPECTOR STEVEN W 4

4 · ARENA PHARMACEUTICALS INC · Filed Sep 10, 2019

Form 4

Period: 2019-09-09

SVP, General Counsel & Sec

Transactions

Exercise/Conversion
Common Stock
2019-09-09$32.50/sh+3,274$106,405→ 22,964 total
Exercise/Conversion
Common Stock
2019-09-09$17.90/sh+5,810$103,999→ 28,774 total
Sale
Common Stock
2019-09-09$51.23/sh−10,257$525,428→ 9,690 total
Sale
Common Stock
2019-09-10$50.28/sh−12,627$634,873→ 9,690 total
Sale
Common Stock
2019-09-09$50.48/sh−21,200$1,070,087→ 19,947 total
Exercise/Conversion
Common Stock
2019-09-10$15.50/sh+12,627$195,719→ 22,317 total
Exercise/Conversion
Employee Stock Option (right to buy)
2019-09-09−3,274→ 3,726 total
Exercise: $32.50Exp: 2020-03-17→ Common Stock (3,274 underlying)
Exercise/Conversion
Employee Stock Option (right to buy)
2019-09-10−12,627→ 27,500 total
Exercise: $15.50Exp: 2023-03-02→ Common Stock (12,627 underlying)
Exercise/Conversion
Common Stock
2019-09-09$15.50/sh+12,373$191,782→ 41,147 total
Exercise/Conversion
Employee Stock Option (right to buy)
2019-09-09−5,810→ 9,189 total
Exercise: $17.90Exp: 2022-12-15→ Common Stock (5,810 underlying)
Exercise/Conversion
Employee Stock Option (right to buy)
2019-09-09−12,373→ 40,127 total
Exercise: $15.50Exp: 2023-03-02→ Common Stock (12,373 underlying)

Footnotes (7)

[F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.99, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes 2, 3, and 4 to this Form 4.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.59, inclusive.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.59, inclusive.
[F5]The options vested in four equal annual installments beginning on March 17, 2011, and were immediately exercisable once vested.
[F6]The options vest in four equal annual installments beginning on December 15, 2016, and are immediately exercisable once vested.
[F7]The options vest in four equal annual installments beginning on March 2, 2017, and are immediately exercisable once vested.

Documents

1 file